Article (Scientific journals)
Protection cardiovasculaire du patient diabetique de type 2 : d'EMPA-REG OUTCOME a LEADER.
Scheen, André; WALLEMACQ, Caroline; Jandrain, Bernard et al.
2016In Revue Médicale Suisse, 12 (527), p. 1370-1375
Peer Reviewed verified by ORBi
 

Files


Full Text
2016 RMS Protection cardiovasculaire du patient D2.pdf
Publisher postprint (580.89 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with type 2 diabetes and high cardiovascular risk. Empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME, and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER, showed a significant reduction in major cardiovascular events (- 14 and - 13 %, respectively), cardiovascular mortality (- 38 and - 22 %, respectively) and all-cause mortality (- 32 and - 15 %, respectively). A lower progression of kidney disease and less renal events were also reported. The underlying protective mechanisms remain controverted as the discussion whether the benefits are specific to each medication or could be extended to other molecules of these two pharmacological classes.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège > Département des sciences cliniques > Département des sciences cliniques
WALLEMACQ, Caroline ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Jandrain, Bernard ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Ernest, Philippe ;  Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Pharmacologie clinique
Language :
French
Title :
Protection cardiovasculaire du patient diabetique de type 2 : d'EMPA-REG OUTCOME a LEADER.
Alternative titles :
[en] Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER
Publication date :
2016
Journal title :
Revue Médicale Suisse
ISSN :
1660-9379
Publisher :
Medecine et Hygiène, Switzerland
Volume :
12
Issue :
527
Pages :
1370-1375
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 08 September 2017

Statistics


Number of views
584 (3 by ULiège)
Number of downloads
421 (2 by ULiège)

Scopus citations®
 
11
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi